Login / Signup

Classification and characteristics of on-label and off-label apixaban use in Denmark and Sweden.

Nicklas VinterMarie LinderMorten AndersenAlma B PedersenMorten MadsenStephen E SchachterleQuazi AtaherJingping MoSøren Paaske JohnsenVera Ehrenstein
Published in: Pharmacoepidemiology and drug safety (2019)
The majority of apixaban initiators in Denmark and Sweden received apixaban for an on-label indication, primarily for NVAF.
Keyphrases
  • venous thromboembolism
  • atrial fibrillation
  • machine learning
  • deep learning